cimicaire à grappes

Reported Uses

• NOTE: see Herb & Supplement Effectiveness Rating Definitions table
• acne [Insufficient Evidence]
• anxiety [Insufficient Evidence]
• breast CA [Insufficient Evidence]
• cardiovascular dz prevention [Insufficient Evidence]
• cognitive function [Insufficient Evidence]
• cough [Insufficient Evidence]
• dysmenorrhea [Insufficient Evidence]
• female infertility [Insufficient Evidence]
• hot flashes, breast CA-related [Insufficient Evidence]
• insect repellent [Insufficient Evidence]
• menopausal sx [Possibly Effective]
• menstrual migraine prophylaxis [Insufficient Evidence]
• osteoarthritis [Insufficient Evidence]
• osteoporosis [Insufficient Evidence]
• parturition [Insufficient Evidence]
• polycystic ovary syndrome [Insufficient Evidence]
• premenstrual syndrome [Insufficient Evidence]
• rheumatoid arthritis [Insufficient Evidence]
• sexual dysfxn [Insufficient Evidence]
• warts [Insufficient Evidence]

Reported Doses

Safety/efficacy may not be established; reported doses may be derived from limited or potentially inadequate studies w/ variable regimens, multi-ingredient products, or where concentration of active ingredients may vary widely

Special Note

[formulation clarification]

Info: products generally stdzd to 1 mg triterpene glycosides

Effectiveness Ratings

[see Herb & Supplement Effectiveness Rating Definitions table]

female infertility

[Insufficient Evidence]

Dose: 120 mg PO qd on days 1-12 of menstrual cycle; Info: used w/ clomiphene given on days 3-7 of menstrual cycle

menopausal sx

[Possibly Effective]

Dose: 8-128 mg/day PO divided qd-bid; Alt: 20 mg PO q12h

menstrual migraine prophylaxis

[Insufficient Evidence]

Dose: 25 mg PO bid; Info: used w/ soy isoflavones and dong quai

osteoarthritis

[Insufficient Evidence]

Dose: 70 mg PO qd

osteoporosis

[Insufficient Evidence]

Dose: 40 mg PO qd

rheumatoid arthritis

[Insufficient Evidence]

Dose: 70 mg PO qd

sexual dysfxn

[Insufficient Evidence]

Dose: 20 mg PO q12h